The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1
Abstract
SphK (sphingosine kinase) is the major source of the bioactive lipid and GPCR (G-protein-coupled receptor) agonist S1P (sphingosine 1-phosphate). S1P promotes cell growth, survival and migration, and is a key regulator of lymphocyte trafficking. Inhibition of S1P signalling has been proposed as a strategy for treatment of inflammatory diseases and cancer. In the present paper we describe the discovery and characterization of PF-543, a novel cell-permeant inhibitor of SphK1. PF-543 inhibits SphK1 with a Ki of 3.6 nM, is sphingosine-competitive and is more than 100-fold selective for SphK1 over the SphK2 isoform. In 1483 head and neck carcinoma cells, which are characterized by high levels of SphK1 expression and an unusually high rate of S1P production, PF-543 decreased the level of endogenous S1P 10-fold with a proportional increase in the level of sphingosine. In contrast with past reports that show that the growth of many cancer cell lines is SphK1-dependent, specific inhibition of SphK1 had no effect on the proliferation and survival of 1483 cells, despite a dramatic change in the cellular S1P/sphingosine ratio. PF-543 was effective as a potent inhibitor of S1P formation in whole blood, indicating that the SphK1 isoform of sphingosine kinase is the major source of S1P in human blood. PF-543 is the most potent inhibitor of SphK1 described to date and it will be useful for dissecting specific roles of SphK1-driven S1P signalling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
Calculation of protein extinction coefficients from amino acid sequence data
Gill, S. C., & von Hippel, P. H. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90602-7 · Cited by 5,283
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate
Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. B., Singh, S. K., Luo, C., Marmorstein, R., Kordula, T., Milstien, S., et al. (2009) · Science · doi:10.1126/science.1176709 · Cited by 997
Ramirez, A., Fisher, G., George, E. L., Sanning, E., Forouzani, M., Allen, J., Bak, R., Halley, W., Wheeler, G., her, et al. (2003) · Cited by 960
Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate
Pappu, R., Schwab, S. R., Cornelissen, I., Pereira, J. P., Regard, J. B., Xu, Y., Camerer, E., Zheng, Y.-W., Huang, Y., Cyster, J. G., et al. (2007) · Science · doi:10.1126/science.1139221 · Cited by 877
Essential Role for Sphingosine Kinases in Neural and Vascular Development
Mizugishi, K., Yamashita, T., Olivera, A., Miller, G. F., Spiegel, S., & Proia, R. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11113-11121.2005 · Cited by 742
“Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
Takabe, K., Paugh, S. W., Milstien, S., & Spiegel, S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07113 · Cited by 718
Liu, H., Sugiura, M., Nava, V. E., Edsall, L. C., Kono, K., Poulton, S., Milstien, S., Kohama, T., & Spiegel, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002759200 · Cited by 667
Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014154108 · Cited by 581
Visentin, B., Vekich, J. A., Sibbald, B. J., Cavalli, A. L., Moreno, K. M., Matteo, R. G., Garland, W. A., Lu, Y., Yu, S., Hall, H. S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.023 · Cited by 463
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
Billich, A., Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N., & Baumruker, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307687200 · Cited by 433
Pettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L., Johnson, K. R., Morrow, J., Chalfant, C. E., Obeid, L. M., & Hannun, Y. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-1038com · Cited by 320
Targeting SphK1 as a New Strategy against Cancer
Shida, D., Takabe, K., Kapitonov, D., Milstien, S., & Spiegel, S. (2008) · Current Drug Targets · doi:10.2174/138945008785132402 · Cited by 307
Dendritic cell PAR1–S1P3 signalling couples coagulation and inflammation
Niessen, F., Schaffner, F., Furlan-Freguia, C., Pawlinski, R., Bhattacharjee, G., Chun, J., Derian, C. K., Andrade-Gordon, P., Rosen, H., & Ruf, W. (2008) · Nature · doi:10.1038/nature06663 · Cited by 280
Sphingosine Kinase: Biochemical and Cellular Regulation and Role in Disease
Taha, T. A., Hannun, Y. A., & Obeid, L. M. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.2.113 · Cited by 276
Pitson, S. M., Xia, P., Leclercq, T. M., Moretti, P. A. B., Zebol, J. R., Lynn, H. E., Wattenberg, B. W., & Vadas, M. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20040559 · Cited by 268
Paugh, S. W., Paugh, B. S., Rahmani, M., Kapitonov, D., Almenara, J. A., Kordula, T., Milstien, S., Adams, J. K., Zipkin, R. E., Grant, S., et al. (2008) · Blood · doi:10.1182/blood-2008-02-138958 · Cited by 244
Antitumor Activity of Sphingosine Kinase Inhibitors
French, K. J., Upson, J. J., Keller, S. N., Zhuang, Y., Yun, J. K., & Smith, C. D. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101345 · Cited by 242
Suppression of Ulcerative Colitis in Mice by Orally Available Inhibitors of Sphingosine Kinase
Maines, L. W., Fitzpatrick, L. R., French, K. J., Zhuang, Y., Xia, Z., Keller, S. N., Upson, J. J., & Smith, C. D. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0133-6 · Cited by 184
Kapitonov, D., Allegood, J. C., Mitchell, C., Hait, N. C., Almenara, J. A., Adams, J. K., Zipkin, R. E., Dent, P., Kordula, T., Milstien, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0664 · Cited by 182
The vascular S1P gradient—Cellular sources and biological significance
HLA, T. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.07.003 · Cited by 180
The LCB4 (YOR171c) and LCB5(YLR260w) Genes of Saccharomyces Encode Sphingoid Long Chain Base Kinases
Nagiec, M. M., Skrzypek, M., Nagiec, E. E., Lester, R. L., & Dickson, R. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.31.19437 · Cited by 180
Self-citationBillich, A., Bornancin, F., Mechtcheriakova, D., Natt, F., Huesken, D., & Baumruker, T. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2004.12.005 · Cited by 139
Anti-Inflammatory Effects of Sphingosine Kinase Modulation in Inflammatory Arthritis
Lai, W.-Q., Irwan, A. W., Goh, H. H., Howe, H. S., Yu, D. T. Y., Valle‐Oñate, R., McInnes, I. B., Melendez, A. J., & Leung, B. P. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8010 · Cited by 134
Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions
Oskeritzian, C. A., Alvarez, S. E., Hait, N. C., Price, M. M., Milstien, S., & Spiegel, S. (2008) · Blood · doi:10.1182/blood-2007-09-115451 · Cited by 118
Wu, Y., Mizugishi, K., Bektas, M., Sandhoff, R., & Proia, R. L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn126 · Cited by 97
Baumruker, T., Billich, A., & Brinkmann, V. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.283 · Cited by 94
Differential regulation of sphingosine kinases 1 and 2 in lung injury
Wadgaonkar, R., Patel, V., Grinkina, N., Romano, C., Liu, J. L., Zhao, Y., Sammani, S., Garcia, J. G. N., & Natarajan, V. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90357.2008 · Cited by 92
A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury
JIN, Z., ZHANG, J., HUANG, Y., Hoover, H. E., Vessey, D. A., & Karliner, J. S. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.05.029 · Cited by 81
Ader, I., Malavaud, B. A., & Cuvillier, O. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0389 · Cited by 76
Kennedy, A. J., Mathews, T. P., Kharel, Y., Field, S. D., Moyer, M. L., East, J. E., Houck, J. D., Lynch, K. R., & Macdonald, T. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2001053 · Cited by 74
Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate
Kharel, Y., Mathews, T. P., Gellett, A. M., Tomsig, J. L., Kennedy, P., Moyer, M. L., Macdonald, T. L., & Lynch, K. R. (2011) · Biochemical Journal · doi:10.1042/bj20110817 · Cited by 74
Sphingosine Kinase Protects Lipopolysaccharide-Activated Macrophages from Apoptosis
Wu, W., Mosteller, R. D., & Broek, D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7359-7369.2004 · Cited by 74
Sphingosine kinase-1 – a potential therapeutic target in cancer
Cuvillier, O. (2006) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328011334d · Cited by 52
Discovery of novel sphingosine kinase 1 inhibitors
Xiang, Y., Asmussen, G., Booker, M. L., Hirth, B. H., Kane, J. L. J., Liao, J., Noson, K. D., & Yee, C. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.022 · Cited by 52
Discovery of novel sphingosine kinase-1 inhibitors. Part 2
Xiang, Y., Hirth, B. H., Kane, J. L. J., Liao, J., Noson, K. D., Yee, C., Asmussen, G., Fitzgerald, M., Klaus, C. R., & Booker, M. L. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.019 · Cited by 46
Pi, X., Tan, S., Hayes, M., Liqun, X., Shayman, J. A., Ling, S., & Holoshitz, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21635 · Cited by 43
Highkin, M. K., Yates, M. P., Nemirovskiy, O. V., LaMarr, W. A., Munie, G. E., Rains, J. W., Masferrer, J. L., & Nagiec, M. M. (2011) · SLAS DISCOVERY · doi:10.1177/1087057110391656 · Cited by 34
Self-citation
Cited by
Sphingolipids and their metabolism in physiology and disease
Hannun, Y. A., & Obeid, L. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.107 · Cited by 2,051
Sphingolipid metabolism in cancer signalling and therapy
Ogretmen, B. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.96 · Cited by 1,207
Sphingosine 1-phosphate: Lipid signaling in pathology and therapy
Cartier, A., & Hla, T. (2019) · Science · doi:10.1126/science.aar5551 · Cited by 613
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy
Proia, R. L., & Hla, T. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76369 · Cited by 528
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Kunkel, G. T., Maceyka, M., Milstien, S., & Spiegel, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4099 · Cited by 434
Metadata
- Authors
- Schnute, M. E., McReynolds, M. D., Kasten, T., Yates, M., Jerome, G., Rains, J. W., Hall, T., Chrencik, J., Kraus, M., Cronin, C. N., Saabye, M., Highkin, M. K., Broadus, R., Ogawa, S., Cukyne, K., Zawadzke, L. E., Peterkin, V., Iyanar, K., Scholten, J. A., Wendling, J., Fujiwara, H., Nemirovskiy, O., Wittwer, A. J., & Nagiec, M. M.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2012-04-26
- Volume
- 444
- Issue
- 1
- Pages
- 79-88
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2134340975
- Cited by
- 280
- References
- 38
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.